| Product Code: ETC9970938 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Multidrug Resistant Bacteria Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Multidrug Resistant Bacteria Market - Industry Life Cycle |
3.4 United States (US) Multidrug Resistant Bacteria Market - Porter's Five Forces |
3.5 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume Share, By Diseases, 2021 & 2031F |
3.6 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume Share, By Pathogen, 2021 & 2031F |
3.7 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.8 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume Share, By End users, 2021 & 2031F |
4 United States (US) Multidrug Resistant Bacteria Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of multidrug-resistant bacteria infections in the US |
4.2.2 Rising awareness about the need for effective antimicrobial stewardship programs |
4.2.3 Technological advancements in diagnostic techniques for detecting multidrug-resistant bacteria strains |
4.3 Market Restraints |
4.3.1 Stringent regulations and policies related to antibiotic use and prescribing practices |
4.3.2 High treatment costs associated with managing multidrug-resistant bacteria infections |
4.3.3 Limited availability of new antibiotics to combat resistant strains |
5 United States (US) Multidrug Resistant Bacteria Market Trends |
6 United States (US) Multidrug Resistant Bacteria Market, By Types |
6.1 United States (US) Multidrug Resistant Bacteria Market, By Diseases |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Diseases, 2021- 2031F |
6.1.3 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Urinary Tract Infection, 2021- 2031F |
6.1.4 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Intra-Abdominal Infections, 2021- 2031F |
6.1.5 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Blood Stream Infections, 2021- 2031F |
6.1.6 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Clostridium Difficile Infections, 2021- 2031F |
6.1.7 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Acute Bacterial Skin and Skin Structure Infections, 2021- 2031F |
6.1.8 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Hospital Acquired Bacterial Pneumonia, 2021- 2031F |
6.2 United States (US) Multidrug Resistant Bacteria Market, By Pathogen |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By E. coli, 2021- 2031F |
6.2.3 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By P. Aeruginosa, 2021- 2031F |
6.2.4 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By K. Pneumoniae, 2021- 2031F |
6.2.5 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Multidrug Resistant Bacteria Market, By Drug Class |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Oxazolidinones, 2021- 2031F |
6.3.3 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Lipoglycopeptides, 2021- 2031F |
6.3.4 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Tetracyclines, 2021- 2031F |
6.3.5 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Cephalosporins, 2021- 2031F |
6.3.6 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Combination Therapies, 2021- 2031F |
6.3.7 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Multidrug Resistant Bacteria Market, By End users |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.5 United States (US) Multidrug Resistant Bacteria Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Multidrug Resistant Bacteria Market Import-Export Trade Statistics |
7.1 United States (US) Multidrug Resistant Bacteria Market Export to Major Countries |
7.2 United States (US) Multidrug Resistant Bacteria Market Imports from Major Countries |
8 United States (US) Multidrug Resistant Bacteria Market Key Performance Indicators |
8.1 Percentage increase in the adoption of antimicrobial stewardship programs in healthcare facilities |
8.2 Number of reported cases of multidrug-resistant bacteria infections in the US |
8.3 Rate of development and approval of new antibiotics targeting resistant strains |
9 United States (US) Multidrug Resistant Bacteria Market - Opportunity Assessment |
9.1 United States (US) Multidrug Resistant Bacteria Market Opportunity Assessment, By Diseases, 2021 & 2031F |
9.2 United States (US) Multidrug Resistant Bacteria Market Opportunity Assessment, By Pathogen, 2021 & 2031F |
9.3 United States (US) Multidrug Resistant Bacteria Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.4 United States (US) Multidrug Resistant Bacteria Market Opportunity Assessment, By End users, 2021 & 2031F |
10 United States (US) Multidrug Resistant Bacteria Market - Competitive Landscape |
10.1 United States (US) Multidrug Resistant Bacteria Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Multidrug Resistant Bacteria Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here